GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in your gut within minutes of eating. It signals to your brain that you are full, tells your pancreas to release insulin, and slows the rate at which your stomach empties its contents into the small intestine.
In people with obesity, GLP-1 production after meals is often insufficient โ meaning the brain never receives adequate satiety signals, making it physiologically harder to feel full and stop eating. GLP-1 receptor agonist medications like semaglutide and tirzepatide work by mimicking and amplifying this natural hormone at a far higher concentration and for a far longer duration than your body can produce on its own.
The result is dramatically reduced appetite, extended feelings of fullness after smaller meals, quieted food cravings, and altered food preferences โ often spontaneously reducing intake of high-fat, high-sugar foods without willpower. This is not a stimulant effect. It is a hormonal realignment that makes eating less feel natural rather than forced.